A New Phase III Trial of ODM-201 for Men with Castrate Resistant Prostate Cancer without Visible Metastases

Bayer HealthCare and Orion Corporation (a Finnish pharmaceutical company) have announced that they have begun enrollment in a randomized Phase III clinical trial of a new investigational treatment for men with advanced prostate cancer. ODM-201 is a novel, oral androgen receptor inhibitor. The trial named ARAMIS trial is a randomized, Phase III, multi-center, double-blind, placebo-controlled [...]

Depression In Men Receiving Androgen Deprivation Therapy (ADT)

Yesterday I wrote about the cognitive effects of hormone therapy (ADT), today’s topic is about depression in men on ADT. It is commonly known that men on ADT often experience many physical and psychological side effects of the treatment. One of these side effects to ADT may be associated with increased risk for depression, but [...]

Chemo-Brain and ADT for Advanced Prostate Cancer – Does It Exist?

When I went on my first round of hormone therapy (ADT) I experienced severe cognitive side effects. I found it impossible to concentrate, read and remember anything. I lost the ability to navigate the New York City subways no less drive my car to a destination. Occasionally, when I was attempting to navigate the subway [...]

Xtandi (enzaludamide) Receives FDA Approval in the Pre-Chemo Stage of Prostate Cancer Treatment

Expected and extraordinary news today on the new treatment front. Medivation and Astellas’ Xtandi (enzalutamide) was approved for use in men with castrate resistant prostate cancer. The new FDA approved label for Xtandi says that it is for the treatment of men with metastatic castration-resistant prostate cancer. This label is basically the same as for [...]

Go to Top